

CURRICULUM VITAE DELL'ATTIVITA' SCIENTIFICA E DIDATTICA

di

Silvia Bruno

Nata a Koblenz (Germania) il 26 ottobre 1960

Cittadinanza: Italiana e Tedesca

TITOLI

Laurea in Fisica, Università degli Studi di Genova, votazione 110/110 e lode, 1984.

Dottore di Ricerca in Biotecnologie, Scuola di Dottorato in Biologia e Medicina Sperimentale, Molecolare e Clinica dell'Università degli Studi di Genova. 2015

Abilitazione Scientifica Nazionale Settore concorsuale **05/H1 Anatomia Umana**.

ATTIVITA' DI RICERCA

- *Incarichi e posizioni*

Università' agli Studi di Genova - Sezione di Anatomia Umana - Dipartimento di Medicina Sperimentale

2017 **Ricercatore a Tempo Determinato tipo B)**, SSC BIO/16 Anatomia Umana

2004-2016 **Assegni di ricerca ai sensi delle Leggi 240/2010 e 449/1997:**

New York Medical College (NYMC), Valhalla, NY, USA.

1990-1992 **Assistant Professor of Medicine**. Appointment.

Memorial Sloan Kettering Cancer Center, New York, USA.

1989-1990 **Visiting investigator**.

Istituto Nazionale per la Ricerca sul Cancro (IST), Genova.

1993-1997

1987- 1988

Contratti Ricercatore ai sensi dell'art.36 DPR 617/80

Hamburg Universitaet, Institut fuer Biophysik und Strahlenbiologie,

1986 **Visiting fellow**.

- *Produzione scientifica*

i) Pubblicazioni scientifiche su riviste internazionali con Impact Factor.

Sono qui di seguito presentati, e presi in considerazione per il calcolo degli indicatori bibliometrici, esclusivamente Articoli pubblicati su riviste con 'peer-review' e indicizzate in Scopus. Non vengono riportati proceedings papers o meeting abstracts.

Indicatori bibliometrici:

Numero pubblicazioni: 72

Citazioni totali: 3976

Impact Factor totale*: 377

* Impact Factor 2015 da Journal Citation report di Web of Science.

H-index: 28

Scopus: Author ID 6602195788

Elenco pubblicazioni scientifiche

Gugiatti E, Tenca C, Ravera S, Fabbi M, Ghiotto F, Mazzarello AN, Bagnara D, Reverberi D, Zarcone D, Cutrona G, Ibatci A, Ciccone E, Darzynkiewicz Z, Fais F, **Bruno S**.

A reversible carnitine palmitoyltransferase I (CPT1) inhibitor offsets chronic lymphocytic leukemia cell proliferation

Haematologica (in press)

Impact Factor: 7.7

Ravera S, Podestà M, Sabatini F, Fresia C, Columbaro M, **Bruno S**, Fulcheri E, Ramenghi LA, Frassoni F.

Mesenchymal stem cells from preterm to term newborns undergo a significant switch from anaerobic glycolysis to the oxidative phosphorylation.

Cell Mol Life Sci 2018 75:889.

Impact Factor: 5.79

Marini C, **Bruno S**, Fiz F, Campi C, Piva R, Cutrona G, Matis S, Nieri A, Miglino M, Ibatci A, Maria Oregno A, Maria Massone A, Neumaier CE, Totero D, Giannoni P, Bauckneht M, Pennone M, Tenca C, Gugiatti E, Bellini A, Borra A, Tedone E, Efetürk H, Rosa F, Emionite L, Cilli M, Bagnara D, Brucato V, Bruzzi P, Piana M, Fais F, Sambuceti G

Functional Activation of Osteoclast Commitment in Chronic Lymphocytic Leukaemia: a Possible Role for RANK/RANKL Pathway.

Sci Rep. 2017 7:14159

Impact Factor: 5.528

Marini C, Ravera S, Buschiazzo A, Bianchi G, Oregno AM, **Bruno S**, Bottoni G, Emionite L, Pastorino F, Monteverde E, Garaboldi L, Martella R, Salani B, Maggi D, Ponzoni M, Fais F, Raffaghello L, Sambuceti G.

Discovery of a novel glucose metabolism in cancer: The role of endoplasmic reticulum beyond glycolysis and pentose phosphate shunt.

Sci Rep. 2016 6:25092.

Impact Factor: 5.528

Puntoni M, Petrera M, Campora S, Garrone E, Defferrari C, Torrisi R, Johansson H, **Bruno S**, Curotto A, DeCensi A.

Prognostic Significance of VEGF after Twenty-Year Follow-up in a Randomized Trial of Fenretinide in Non-Muscle-Invasive Bladder Cancer.

Cancer Prev Res. 2016 9:437-44.

Impact Factor: 3.887

Bruno S, Ledda B, Tenca C, Ravera S, Oregno AM, Mazzarello AN, Pesenti E, Casciaro S, Racchi O, Ghiotto F, Marini C, Sambuceti G, DeCensi A, Fais F.

Metformin inhibits cell cycle progression of B-cell chronic lymphocytic leukemia cells.

Oncotarget. 2015 6:22624-40.

Impact Factor: 5.008

Cossu I, Bottoni G, Loi M, Emionite L, Bartolini A, Di Paolo D, Brignole C, Piaggio F, Perri P, Sacchi A, Curnis F, Gagliani MC, **Bruno S**, Marini C, Gori A, Longhi R, Murgia D, Sementa AR, Cilli M, Tacchetti C, Corti A, Sambuceti G, Marchiò S, Ponzoni M, Pastorino F.
Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion.
Biomaterials. 2015 68:89-99.
Impact Factor: **8.387**

Caci E, Scudieri P, Di Carlo E, Morelli P, **Bruno S**, De Fino I, Bragonzi A, Gianotti A, Sondo E, Ferrera L, Palleschi A, Santambrogio L, Ravazzolo R, Galiotta LJ.
Upregulation of TMEM16A Protein in Bronchial Epithelial Cells by Bacterial Pyocyanin.
PLoS One. 2015 10:e0131775.
Impact Factor: **3.057**

Marcatili P, Ghiotto F, Tenca C, Chailyan A, Mazzarello AN, Yan XJ, Colombo M, Albesiano E, Bagnara D, Cutrona G, Morabito F, **Bruno S**, Ferrarini M, Chiorazzi N, Tramontano A, Fais F.
Igs expressed by chronic lymphocytic leukemia B cells show limited binding-site structure variability.
J Immunol. 2013 190:5771-8
Impact Factor: **4.985**

Colombo M, Cutrona G, Reverberi D, **Bruno S**, Ghiotto F, Tenca C, Stamatopoulos K, Hadzidimitriou A, Ceccarelli J, Salvi S, Boccardo S, Calevo MG, De Santanna A, Truini M, Fais F, Ferrarini M.
Expression of immunoglobulin receptors with distinctive features indicating antigen selection by marginal zone B cells from human spleen.
Mol Med. 2013 19:294-302.
Impact Factor : **3.530**

Bruno S, Ghiotto F, Tenca C, Mazzarello A, Bono M, Luzzi P, Casciaro S, Recchia A, DeCensi A, Morabito F and Fais F.
N-(4-hydroxyphenyl)retinamide promotes apoptosis of resting and proliferating B-cell chronic lymphocytic leukemia cells and potentiates Fludarabine and ABT-737 cytotoxicity.
Leukemia 2012 26:2260-8.
Impact Factor: **12.104**

Scudieri P, Caci E, **Bruno S**, Ferrera L, Schiavon M, Sondo E, Tomati V, Gianotto A, Zegarra-Moran O, Pedemonte N, Rea F, Ravazzolo R, Galiotta LJV.
Association of TMEM16A chloride channel overexpression with airway goblet cell metaplasia.
J Cellular Physiol 2012 590: 6141-6155
Impact Factor: **4.155**

Ghiotto F, Marcatili P, Tenca C, Calevo MG, Yan XJ, Albesiano E, Bagnara D, Colombo M, Cutrona G, Chu CC, Morabito F, **Bruno S**, Ferrarini M, Tramontano A, Fais F, Chiorazzi N.
Mutation pattern of paired immunoglobulin heavy and light variable domains in chronic lymphocytic leukemia B cells.
Mol Med. 2011 17:1188-95
Impact Factor : **3.530**

Di Paolo D, Brignole C, Pastorino F, Carosio R, Zorzoli A, Rossi M, Loi M, Pagnan G, Emionite L, Cilli M, **Bruno S**, Chiarle R, Allen TM, Ponzoni M and Perri P.
Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK.
Mol Ther 2011 19:1131-1140.
Impact Factor: **6.938**

Scapolan O, Mazzarello AN, Bono M, Occhino M, Ogryzko V, Bestagno M, Scartezzini P, **Bruno S**, Fais F, Ghiotto F.

A Vector Design that Allows Fast and Convenient Production of Differently Tagged Proteins.
Mol Biotechnol. 2011 52:16-25

Impact Factor: 1.752

Ghiotto F, Fais F, **Bruno S**.

BH3-only proteins: the death-puppeteer's wires.

Cytometry 2010 77:11-21.

Impact Factor: 3.181

Ghiotto F, Fais F, Tenca C, Tomati V, Morabito F, Casciaro S, Mumot A, Zoppoli G, Ciccone E, Parodi S, **Bruno S**.

[Apoptosis of B-cell chronic lymphocytic leukemia cells induced by a novel BH3 peptidomimetic.](#)

Cancer Biol Ther. 2009 8:263-81.

Impact Factor: 2.921

Ponassi R, Biasotti B, Tomati V, **Bruno S**, Poggi A, Malacarne D, Cimoli G, Salis A, Pozzi S, Miglino M, Damonte G, Cozzini P, Spyraiki F, Campanini B, Bagnasco L, Castagnino N, Tortolina L, Mumot A, Frassoni F, Daga A, Cilli M, Piccardi F, Monfardini I, Perugini M, Zoppoli G, D'Arrigo C, Pesenti R, Parodi S.

[A novel Bim-BH3-derived Bcl-XL inhibitor: biochemical characterization, in vitro, in vivo and ex-vivo anti-leukemic activity.](#)

Cell Cycle. 2008 7:3211-24.

Impact Factor: 3.952

Maffei M, Ghiotto F, Occhino M, Bono M, De Santanna A, Battini L, Gusella GL, Fais F, **Bruno S**, Ciccone E.

The human cytomegalovirus regulates surface expression of the viral protein UL18 by means of two motifs present in the cytoplasmic tail.

J Immunol. 2008 180:969-79.

Impact Factor: 4.985

Occhino M, Ghiotto F, Soro S, Mortarino M, Bosi S, Maffei M, **Bruno S**, Nardini M, Figini M, Tramontano A, Ciccone E.

Dissecting the structural determinants of the interaction between the HCMV UL18 protein and the CD85j immune receptor.

J Immunol. 2008 180:957-68.

Impact Factor: 4.985

Puntoni M, Zanardi S, Branchi D, **Bruno S**, Curotto A, Varaldo M, Bruzzi P, Decensi A.

Prognostic effect of DNA aneuploidy from bladder washings in superficial bladder cancer.

Cancer Epidem Biomar 2007 16:979-83.

Impact Factor: 3.622

Saverino D, Ghiotto F, Merlo A, **Bruno S**, Battini L, Occhino M, Maffei M, Tenca C, Pileri S, Baldi L, Fabbi M, Bachi A, De Santanna A, Grossi CE, Ciccone E.

Specific recognition of the viral protein UL18 by CD85j/LIR-1/ILT2 on CD8+ T cells mediates the non-MHC-restricted lysis of human cytomegalovirus-infected cells.

J Immunol. 2004 172:5629-37.

Impact Factor: 4.985

Bruno S, Ghiotto F, Fais F, Fagioli M, Luzi L, Pelicci PG, Grossi CE, Ciccone E.

The PML gene is not involved in the regulation of MHC class I expression in human cell lines.

Blood. 2003 101:3514-19.

Impact Factor: 11.847

Tenca C, Merlo A, Zarccone D, Saverino D, **Bruno S**, De Santanna A, Ramarli D, Fabbi M, Pesce C, Deaglio S, Ciccone E, Malavasi F, Grossi CE.

Death of T cell precursors in the human thymus: a role for CD38.

Int Immunol. 2003 15:1105-16.

Impact Factor: 3.031

Airoidi I, Lualdi S, **Bruno S**, Raffaghello L, Occhino M, Gambini C, Pistoia V, Corrias MV.
Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L.
Br J Cancer. 2003 88:1527-36.
Impact Factor: 5.569

Bruno S, Tenca C, Saverino D, Ciccone E, Grossi CE.
Apoptosis of squamous cells at different stages of carcinogenesis following 4-HPR treatment.
Carcinogenesis 2002 23:447-56
Impact Factor: 4.874

Saverino D, Merlo A, **Bruno S**, Pistoia V, Grossi CE, Ciccone E.
Dual effect of CD85/LIR-1/ILT2 and CD152(CTLA-4) on cytokine production by antigen-stimulated human T cells.
J Immunol 2002 168:207-215.
Impact Factor: 4.985

Pescarolo MP, Bagnasco L, Malacarne D, Melchiori A, Valente P, Millo E, **Bruno S**, Basso S, Parodi S.
A retro-inverso peptide homologous to helix 1 of c-Myc is a potent and specific inhibitor of proliferation in different cellular systems.
FASEB J. 2001 15:31-33.
Impact Factor: 5.299

Merlo A, Saverino D, Tenca C, Grossi CE, **Bruno S**, Ciccone E.
CD85/LIR-1/ILT2 and CD152 (cytotoxic T lymphocyte antigen 4) inhibitory molecules down-regulate the cytolytic activity of human CD4+ T-cell clones specific for Mycobacterium tuberculosis.
Infect Immun. 2001 69:6022-29.
Impact Factor: 3.603

Loprevite M, Favoni RE, de Cupis A, Pirani P, Pietra G, **Bruno S**, Grossi F, Scolaro T, Ardizzoni A.
Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines.
Lung Cancer. 2001 33:27-39.
Impact Factor: 3.767

Saverino D, Fabbi M, Ghiotto F, Merlo A, **Bruno S**, Zarccone D, Tenca C, Tiso M, Santoro G, Anastasi G, Cosman D, Grossi CE, Ciccone E.
The CD85/LIR-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and down-regulates their functions.
J Immunol 2000 165:3742-55.
Impact Factor: 4.985

Bruno S, Fabbi M, Tiso M, Santamaria B, Ghiotto F, Saverino D, Tenca C, Zarccone D, Ferrini S, Ciccone E, Grossi CE.
Cell activation via CD44 occurs in advanced stages of squamous cell carcinogenesis.
Carcinogenesis. 2000 21:893-900.
Impact Factor: 4.874

Decensi A, Torrìs R, **Bruno S**, Costantini M, Curotto A, Nicolò G, Malcangi B, Baglietto L, Bruttini GP, Gatteschi B, Rondanina G, Varaldo M, Perloff M, Malone WF, Bruzzi P.
Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point.
Cancer Epidemiol Biomarkers Prev. 2000 9:1071-78.
Impact Factor: 3.622

Bruno S, Torrisci R, Costantini M, Baglietto L, Fontana V, Gatteschi B, Melioli G, Nicolo G, Curotto A, Malcangi B, Bruttini GP, Varaldo M, Bruzzi P, Decensi A.
Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial.
J Cell Biochem. 1999 76:311-21.
Impact Factor: 3.446

Giorello L, Clerico L, Pescarolo MP, Vikhanskaya F, Salmona M, Colella G, **Bruno S**, Mancuso T, Bagnasco L, Russo P, Parodi S.
Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence.
Cancer Res. 1998 58:3654-9.
Impact factor: 8.556

Favoni R E, De Cupis A, **Bruno S**, Yee D, Ferrera A, Pirani P, Costa A, Decensi A.
Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines.
Br J Cancer. 1998 77:2138-47.
Impact Factor: 5.569

Darzynkiewicz Z, **Bruno S**, Del Bino G, Traganos F.
The cell cycle effects of camptothecin.
Ann N Y Acad Sci. 1996 803:93-100.
Impact Factor: 4.518

Hara S, Halicka HD, **Bruno S**, Gong J, Traganos F, Darzynkiewicz Z.
Effect of protease inhibitors on early events of apoptosis.
Exp Cell Res. 1996 223:372-84.
Impact factor: 3.378

Ferlazzo G, Magno C, Iemmo R, Rizzo M, Lupo G, Semino C, **Bruno S**, Melioli G.
Treatment of superficial bladder cancer with intravesical perfusion of rIL-2: a follow-up study.
Anticancer Res. 1996 16:979-80.
Impact factor: 1.895

Decensi A, Fontana V, **Bruno S**, Gustavino C, Gatteschi B, Costa A.
Effect of tamoxifen on endometrial proliferation.
J Clin Oncol. 1996 14:434-40.
Impact factor: 20.982

Bruno S, Machi AM, Semino C, Meta M, Ponte M, Varaldo M, Curotto A, Ferlazzo G, Decensi A, Melioli G.
Phenotypic, functional and molecular analysis of lymphocytes associated with bladder cancer.
Cancer Immunol Immunother. 1996 42:47-54.
Impact Factor: 4.846

Guglielmi A, Aschele C, Mori A, Baldo C, Russo P, Debernardis D, Valenti M, **Bruno S**, Taverna M, Rosso R, et al.
In vitro synergism between 5-fluorouracil and natural beta interferon in human colon carcinoma cells.
Clin Cancer Res. 1995 1:1337-44.
Impact factor: 8.738

Decensi A, **Bruno S**, Costantini M, Torrisci R, Curotto A, Gatteschi B, Nicolo G, Polizzi A, Perloff M, Malone WF, et al.
Phase IIa study of fenretinide in superficial bladder cancer, using DNA flow cytometry as an intermediate end point.
J Natl Cancer Inst. 1994 86:138-40.

Impact Factor: 11.370

Decensi A, **Bruno S**, Torrisi R, Parodi S, Polizzi A.
Pilot study of high dose fenretinide and vitamin A supplementation in bladder cancer.
Eur J Cancer. 1994 30A: 1909-10.
Impact Factor: 6.163

Strife A, Perez A, Lambek C, Wisniewski D, **Bruno S**, Darzynkiewicz Z, Clarkson B
Differences in the composition and in the efficiency of red cell production of normal and CML erythroid progenitor populations are highlighted by response to human c-kit ligand.
Leuk Res. 1993 17:799-807.
Impact Factor: 2.606

Capasso JM, **Bruno S**, Li P, Zhang X, Darzynkiewicz Z, Anversa P.
Myocyte DNA synthesis with aging: correlation with ventricular loading in rats.
J Cell Physiol. 1993 155:635-48.
Impact Factor: 4.155

Strife A, Perez A, Lambek C, Wisniewski D, **Bruno S**, Darzynkiewicz Z, Clarkson B.
Characterization of lineage-negative blast subpopulations derived from normal and chronic myelogenous leukemia bone marrows and determination of their responsiveness to human c-kit ligand.
Cancer Res. 1993 53:401-9.
Impact factor: 8.556

Bruno S, Ardeli B, Skierski JS, Traganos F, Darzynkiewicz Z.
Different effects of staurosporine, an inhibitor of protein kinases, on the cell cycle and chromatin structure of normal and leukemic lymphocytes.
Cancer Res. 1992 52:470-3.
Impact factor: 8.556

Bruno S, Del Bino G, Lassota P, Giaretti W, Darzynkiewicz Z.
Inhibitors of proteases prevent endonucleolysis accompanying apoptotic death of HL-60 leukemic cells and normal thymocytes.
Leukemia. 1992 6:1113-20.
Impact Factor: 12.104

Bruno S, Giaretti W, Darzynkiewicz Z.
Effect of camptothecin on mitogenic stimulation of human lymphocytes: involvement of DNA topoisomerase I in cell transition from G₀ to G₁ phase of the cell cycle and in DNA replication.
J Cell Physiol. 1992 151:478-86.
Impact Factor: 4.155

Bruno S, Darzynkiewicz Z.
Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells.
Cell Prolif. 1992 25:31-40.
Impact Factor: 3.084

Bruno S, Lassota P, Giaretti W, Darzynkiewicz Z.
Apoptosis of rat thymocytes triggered by prednisolone, camptothecin, or teniposide is selective to G₀ cells and is prevented by inhibitors of proteases.
Oncol Res. 1992 4:29-35.
Impact Factor: 3.957

Bruno S, Gorczyca W, Darzynkiewicz Z.
Effect of ionic strength in immunocytochemical detection of the proliferation associated nuclear antigens p120, PCNA, and the protein reacting with Ki-67 antibody.

Cytometry. 1992 13:496-501.
Impact Factor: 3.181

Darzynkiewicz Z, **Bruno S**, Del Bino G, Gorczyca W, Hotz MA, Lassota P, Traganos F.
Features of apoptotic cells measured by flow cytometry.
Cytometry. 1992 13:795-808.
Impact Factor: 3.181

Capasso JM, **Bruno S**, Cheng W, Li P, Rodgers R, Darzynkiewicz Z, Anversa P.
Ventricular loading is coupled with DNA synthesis in adult cardiac myocytes after acute and chronic myocardial infarction in rats.
Circ Res. 1992 71:1379-89.
Impact Factor: 9.004

Traganos F, Ardelt B, Halko N, **Bruno S**, Darzynkiewicz Z.
Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells.
Cancer Res. 1992 52:6200-8.
Citations: 173
Impact factor: 8.556

Gorczyca W, **Bruno S**, Melamed MR, Darzynkiewicz Z.
Cell cycle-related expression of p120 nucleolar antigen in normal human lymphocytes and in cells of HL-60 and MOLT-4 leukemic lines: effects of methotrexate, camptothecin, and teniposide.
Cancer Res. 1992 52:3491-4.
Impact factor: 8.556

Rivas CI, Wisniewski D, Strife A, Perez A, Lambek C, **Bruno S**, Darzynkiewicz Z, Clarkson B.
Constitutive expression of p53 protein in enriched normal human marrow blast cell populations.
Blood. 1992 79:1982-6.
Impact Factor: 11.847

Del Bino G, **Bruno S**, Yi PN, Darzynkiewicz Z.
Apoptotic cell death triggered by camptothecin or teniposide. The cell cycle specificity and effects of ionizing radiation.
Cell Prolif. 1992 25:537-48.
Impact Factor 3.084

Minks M, Di Vinci A, **Bruno S**, Geido E, Avignolo C, Giaretti W.
Interleukin-3 dependent c-myc protein expression during the cell cycle of murine mast cells.
Cancer Lett. 1992 62:243-9.
Impact Factor: 5.992

Bruno S, Crissman HA, Bauer KD, Darzynkiewicz Z.
Changes in cell nuclei during S phase: progressive chromatin condensation and altered expression of the proliferation-associated nuclear proteins Ki-67, cyclin (PCNA), p105, and p34.
Exp Cell Res. 1991 196:99-106.
Impact factor: 3.378

Jakobisiak M, **Bruno S**, Skierski JS, Darzynkiewicz Z.
Cell cycle-specific effects of lovastatin.
Proc Natl Acad Sci U S A. 1991 88:3628-32.
Impact Factor: 9.423

Nusse M, Julch M, Geido E, **Bruno S**, Di Vinci A, Giaretti W, Ruoss K.
Flow cytometric detection of mitotic cells using the bromodeoxyuridine/DNA technique in combination with 90 degrees and forward scatter measurements.
Cytometry. 1989 10:312-9.

Impact Factor **3.181**

Giaretti W, Sciallero S, **Bruno S**, Geido E, Aste H, Di Vinci A.
DNA flow cytometry of endoscopically examined colorectal adenomas and adenocarcinomas.
Cytometry. 1988 9:238-44.
Impact Factor **3.181**

Sciallero S, **Bruno S**, Di Vinci A, Geido E, Aste H, Giaretti W.
Flow cytometric DNA ploidy in colorectal adenomas and family history of colorectal cancer.
Cancer. 1988 61:114-20.
Impact Factor **5.649**

Bruno S, Di Vinci A, Geido E, Giaretti W.
Cell cycle synchronization induced by tamoxifen and 17 beta-estradiol on MCF-7 cells using flow
cytometry and a monoclonal antibody against bromodeoxyuridine.
Breast Cancer Res Treat. 1988 11:221-9.
Impact Factor: **4.085**

ii) Capitoli in libri o a invito in special issues di riviste scientifiche

Ghiotto F, Tenca C, Fais F and **Bruno S**:
BH3-only proteins in cancer and apoptosis. In: Trends in Stem Cell Proliferation and Cancer
Research. Resende RR and Ulrich H (eds.). Springer, 2013 ISBN 978-94-007-6210-7.

Darzynkiewicz Z, Gorczyca W, Hotz MA, Lassota P, **Bruno S** and Traganos F:
Chromatin Changes Accompanying Apoptosis Detected by Flow Cytometry. In: Flow Cytometry:
New Developments. A. Jacquemin-Sablon (ed.), Springer-Verlag, Paris; NATO ASI Series, 1993,
pp. 311-326. ISBN 978-3-642-84616-8

Fais F, Tenca C, Ghiotto F and **Bruno S**:
Targeting the Bcl-2 family in B-cell chronic lymphocytic leukemia. [International Journal of
Hematologic Oncology](#). Future Medicine, London, 2013 ISSN: 2045-1393 DOI 10.2217/ijh.13.43

Bruno S, Traganos F and Darzynkiewicz Z:
Cell cycle synchronizing properties of staurosporine. Meth Cell Science, Special Issue on
'Mammalian Synchronization properties in vitro' . Erba E. and Soumitra S. (eds.). Kluwer
Academic Publishers, 1996 volume 18, pages 99-107. ISSN: 1381-5741
doi:10.1007/BF00122160

Melioli G and **Bruno S**:
Tecniche di immunometria in citometria a flusso. Ed: Forum Service, 1996.

iii) Comunicazioni orali SU INVITO o selezionate

LXXI Congresso della Società Italiana di Anatomia e Istologia. Taormina, September 2017
Gugiatti E, Tenca C, Ravera S, Ghiotto F, Cutrona G, Ibatici A, Ciccone E, Fais F, **Bruno S**. A
reversible carnitine palmitoyltransferase I (CPT1) inhibitor offsets chronic lymphocytic leukemia
cell proliferation

Invited Key Note speaker, 53. British Society of Hematology , Liverpool, 13-16 April 2013.
Targeting the Bcl-2 family on CLL

Invited speaker, 14. Leipziger Workshop (Cytomics and Regenerative Medicine), Leipzig 2-4
April 2009. Sonata a tre: hitting the right target in hematological malignancies?

XIII International Workshop on Chronic Lymphocytic Leukemia. Barcelona, Spain, 16-18 October 2009.

Bruno S, Ghiotto F, Tenca C, Luzzi P, Fais F: Activity of 4-HPR on in vitro cultured leukemic B cells derived from CLL patients.

LXII Congresso della Società Italiana di Anatomia e Istologia. Verona, 14-16 September 2008

Bruno S, Ghiotto F, Tenca C, Luzzi P, Parodi S, Fais F: Apoptosis induction by oxidative stress and Mcl-1/ Bcl-XL down-regulation in chronic B-cell lymphocytic leukemia.

XXII Congress of the International Society for Analytical Cytology. Montpellier, France, 22-27 May 2004.

Bruno S, Ghiotto F, Fais F, Grossi CE and Ciccone E: Is human PML gene involved in the regulation of MHC class I antigen presentation?

LVIII Congresso della Società Italiana di Anatomia. Chieti, 17-19 September 2004.

Bruno S, Occhino M, Maffei M, Ghiotto F, Fais F, Grossi CE, Ciccone E: Perinucleolar localization of human gamma-tubulin.

XV Congress of the International Society for Analytical Cytology. Bergen, Norway, 25-30 August 1991.

Bruno S, Jakobisiak M, Skiersky J, Darzynkiewicz Z: The cell cycle specific effects of Lovastatine.

- ***Partecipazione a Progetti di Ricerca***

2015-2017 **AIRC (Associazione Italiana per la Ricerca sul Cancro).** ‘Restricted variability of B-cell receptor 3D structures in chronic lymphocytic leukemia: clinico-biological relevance’ (Resp. Franco Fais)

2010-2012 **AIRC** ‘3D structure analysis of Chronic Lymphocytic Leukemia B-cell Receptor: biological and clinical relevance’. (Resp. Franco Fais)

2008-2012 **Compagnia di San Paolo (Torino)** Meccanismi antigene-dipendenti e antigene-indipendenti coinvolti nella patogenesi della leucemia linfatica cronica-B. (Resp. Franco Fais)

2005-2006 **PRIN** ‘Interazione fra linfociti CD1d-ristretti e cellule B di leucemia linfatica cronica’. (Resp. Carlo E. Grossi)

2003-2004 **PRIN** ‘Effetto di PML sulla regolazione della via endogena di presentazione dell’antigene e alterata immunogenicità delle cellule leucemiche’. (Resp. Ermanno Ciccone)

2002-2006 **Compagnia di San Paolo (Torino)** Prog. 2002.0681 Controllo dell’infezione da citomegalovirus umano da parter del sistema immunitario: nuovi meccanismi molecolari non MHC-ristretti dei linfociti T che permette l’eliminazione delle cellule infettate da hCMV. (Resp. Ermanno Ciccone)

2001-2003 **AIRC** ‘Role of CD85j/LIR-1 regulation in T cell anergy and tumor recognition’. (Resp. Ermanno Ciccone)

2001-2006 **FIRB** ‘Ectoenzimi leucocitari e loro coinvolgimento nella patogenesi: diagnosi e terapia di selezionate patologie umane’. (Resp. Carlo E. Grossi)

2001-2002 **PRIN** ‘Regolazione dei geni MHC di classe I da parte di PML e immunogenicità delle cellule leucemiche’. (Resp. Ermanno Ciccone)

2000-2001 **PRIN** ‘Analisi morfologica e molecolare dell’attivazione delle cellule NK mediata attraverso la via CD38’ (Resp. Carlo E. Grossi)

1998-2000 **AIRC** ‘Does inhibition mediated by CTLA-4 provide tumor cells with a mechanism to escape from immune surveillance?’ (Resp. Ermanno Ciccone)

1999-2000 **PRIN** ‘Regolazione dei geni MHC di classe I da parte di PML e conseguente diminuita immunogenicità delle cellule leucemiche’.(Resp. Ermanno Ciccone)

1998-2000 **AIRC** ‘Squamous cell carcinogenesis: is there a role for CD44 in cell proliferation and death?’ (Resp. Carlo E. Grossi)

1994-1997 **NCI-NIH (National Cancer Institute- National Institute for Health, USA)**
Progetto 5UO1 CA56457: Fenretinide: chemoprevention in superficial bladder cancer (clinical trial).(Resp. Andrea DeCensi)

1990-1992 **NHLBI (National Heart, Lung and Blood Institute, USA)** Progetto HL-40561 ‘Aging of the myocardium and myocyte cell proliferation’. (Resp: Piero Anversa)

1989-1993 **NCI-NIH (National Cancer Institute- National Institute for Health, USA)**
Progetto R37 CA23296 ‘New antitumor drugs’ (Resp. Zbigniew Darzynkiewicz)

1989-1993 **NCI-NIH (National Cancer Institute- National Institute for Health, USA)**
Progetto R01 CA28704 ‘Apoptosis by antitumor drugs (pre-clinical)’.(Resp. Zbigniew Darzynkiewicz).

ATTIVITA' DIDATTICA

Università degli Studi di Genova, Facoltà di Medicina e Chirurgia
Docente titolare dell’insegnamento ‘**Anatomia Umana**’ Corso di Laurea Farmacia
Anno Accademico 2017-2018

Università degli Studi di Genova, Facoltà di Medicina e Chirurgia
Professore a Contratto per Insegnamento di ‘Anatomia Umana: Perfusione Cardiovascolare’, nell’ambito del Corso Integrato di Anatomia e Istologia. Corso di Laurea in “Tecniche di fisiopatologia cardiocircolatoria e perfusione cardiovascolare”.
Anno Accademico 2010-2011

Università degli Studi di Genova, Facoltà di Medicina e Chirurgia
Professore a Contratto per Insegnamento ‘Anatomia dell’Apparato Digerente’ nell’ambito del Corso Integrato di Anatomia e Istologia. Corso di Laurea in “Dietistica”
Anno Accademico 2010-2011

Università degli Studi di Genova, Facoltà di Medicina e Chirurgia
Incarico di Supporto alla Didattica (art.33 dello Statuto dell’Università di Genova) nell’ambito del Corso Integrato di Anatomia e Istologia, Corso di Laurea in “Infermieristica”
Anno Accademico 2009-2010

Università degli Studi di Genova, Facoltà di Medicina e Chirurgia
Incarico di Supporto alla Didattica (art.33 dello Statuto dell’Università di Genova) nell’ambito del Corso Integrato di Anatomia e Istologia. Corso di Laurea in “Tecniche di fisiopatologia cardiocircolatoria e perfusione cardiovascolare”
Anno Accademico 2008-2009

Università degli Studi di Genova, Facoltà di Medicina e Chirurgia:
Professore a contratto per l’Insegnamento di ‘Analisi multiparametrica’ nell’ambito del Corso di Perfezionamento in ‘Citometria’.
Anni Accademici 1995-1996 , 1996-1997 , 1997-1998 , 1998-1999

Genova 25 maggio 2018